Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. NVDA
2. MIRM
3. USO
4. SHEL
5. LLY
6. META
7. MU
8. MRK
9. ACN
10. SPY

Go back to Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
(NASDAQ: FULC) Delayed: 3.74 --0 (-0%)
Previous Close $3.74    52 Week High $ 
Open $3.74    52 Week Low $ 
Day High $3.74    P/E N/A 
Day Low $3.74    EPS $ 
Volume 100       

SANOFI (NASDAQ: SNY) Delayed: 41.11 --0 (-0%)
Previous Close $41.11    52 Week High $44.76 
Open $41.11    52 Week Low $36.81 
Day High $41.11    P/E N/A 
Day Low $41.11    EPS $0.00 
Volume 10,888